Ex-Dividend Stocks: Boeing, Wal-Mart, Pfizer
"Following 1Q12 results that were 5% below our forecasts we have trimmed FY12 EPS and beyond by c2-3%," Bank of America Merrill Lynch analysts wrote in a May 4 report. "Changes are mostly driven by sales (emerging markets and FX) with margins unchanged and an increased Buyback (to £3.5bn from £3bn excluding HGSI offer which would see this fall to £2bn) offering some small offset. Despite cuts our forecasts remain c3-4% above consensus near-term and c17% above consensus buy 2016 mostly due to higher buybacks. Maintain buy for superior growth, pipeline upside and income."
Forward Annual Dividend Yield: 4.8%
The drug company reported on May 1 first-quarter earnings of $4.4 billion, or 58 cents a share, down from year-earlier earnings of $4.8 billion, or 60 cents.
"We believe that continued strong cash flow generation, focus on shareholder return through a stable and growing dividend and significant share buybacks, expense control, and potential for positive pipeline news could improve sentiment over time and lead to multiple expansion," Bank of America Merrill Lynch analysts wrote in a report Monday.
Forward Annual Dividend Yield: 3.9%